Under the multi-year collaboration, the companies will seek to deploy multiple AI-powered software solutions that will be able to identify hidden cardiovascular conditions.
They will deliver electrocardiogram (ECG) AI algorithms that will enable physicians to improve the detection of heart diseases in patients with no prior history.
Currently, the algorithms are under development and have not been cleared by US Food and Drug Administration (FDA) for commercial clinical use.
“Bringing together premier global organisations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”
Anumana aims to deliver an AI-based offering that can enable diagnostic software to pick up signals from ECGs that humans cannot recognise.
It will also deliver AI-based technology that can identify atherosclerotic cardiovascular disease.
Additionally, the collaboration will develop an evidence-based, digital point-of-care solution to optimise guideline-directed medical therapies to reduce hospitalisation risks and potential death due to cardiovascular disease.
Novartis Innovative Medicines US president Victor Bulto said: “Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care.
“Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”
Notably, Anumana ’s AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm secured FDA Breakthrough Device Designation in May.